A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 360
Summary
- Conditions
- Chemotherapy Effect
- Lung Cancer Squamous Cell
- Lung Cancer Stage IV
- PD-1 Antibody
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
In this study, eligible subject will be randomized into study arm or control arm to accept study treatment. Subjects who randomized into control will have the opportunity to receive cross over treatment of SHR-1210 monotherapy after confirmed disease progression. Treatment cycles of chemotherapy wil...
In this study, eligible subject will be randomized into study arm or control arm to accept study treatment. Subjects who randomized into control will have the opportunity to receive cross over treatment of SHR-1210 monotherapy after confirmed disease progression. Treatment cycles of chemotherapy will be 4-6 which will be decided by investigators.
Tracking Information
- NCT #
- NCT03668496
- Collaborators
- Not Provided
- Investigators
- Study Director: Jianjun Zou, MD, PhD Jiangsu HengRui Medicine Co., Ltd. Principal Investigator: Caicun Zhou, MD, PhD Tongji University, Shanghai Pulmonary Hospital